Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation<blockquote>随着FDA批准其Lomecel-B用于罕见儿科疾病指定,Longeveron在盘前交易中继续攀升超过50%</blockquote>
Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare p
